Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso

Amidou Diarra1*, Issa Nebie1, Alfred Tiono1, Issiaka Soulama1, Alphonse Ouedraogo1, Amadou Konate1, Michael Theisen2, Daniel Dodoo3, Alfred Traore4 and Sodiomon B Sirima1,5

Abstract

Background: Patient immune status is thought to affect the efficacy of anti-malarial chemotherapy. This is a subject of some importance, since evidence of immunity-related interactions may influence our use of chemotherapy in populations with drug resistance, as well as assessment of the value of suboptimal vaccines. The study aim was to investigate relationship between antibodies and anti-malarial drug treatment outcomes.

Methods: Some 248 children aged 0.5 and 15 years were recruited prior to the high malaria transmission season. Venous blood (5 ml) was obtained from each child to measure antibody levels to selected malaria antigens, using ELISA. Blood smears were also performed to assess drug efficacy and malaria infection prevalence. Children were actively followed up to record clinical malaria cases.

Results: IgG levels to MSP3 were always higher in the successfully treated group than in the group with treatment failure. The same observation was made for GLURP but the reverse observation was noticed for MSP1-19. Cytophilic and non-cytophilic antibodies were significantly associated with protection against all three antigens, except for IgG4 to MSP1-19 and GLURP.

Conclusion: Acquired anti-malarial antibodies may play an important role in the efficacy of anti-malarial drugs in younger children more susceptible to the disease.

Keywords: Antibodies, Chloroquine, Sulphadoxine/pyrimethamine, MSP3, GLURP, MSP1-19

Background

In areas of endemic parasite transmission, protective immunity to Plasmodium falciparum malaria is acquired over several years, in response to numerous disease episodes. In vitro studies have shown that antibodies against some malaria vaccine candidates (GLURP, MSP3, and MSP1-19) play a protective role against malaria[1,2]. In addition, epidemiological studies have shown that immunity acquired over several years is strongly related to a drop in mortality and morbidity within populations living in malaria-endemic areas[3]. Although anti-malarial vaccines are being produced and tested, the control of malaria relies heavily on chemotherapy[4,5]. Many of the available anti-malarial drugs are effective, cheap, and easy to distribute. However, in recent years, the increase in drug resistance throughout malaria-endemic regions has been cause for great concern, and has led to calls for the development of new anti-malarial measures, which would involve a larger variety of drug targets as well as a wider array of vaccine strategies[6,7]. In this context, any strategies that maximize the effectiveness of drugs or suboptimal vaccines may lead to significant progress. Among the factors upon which the efficacy of anti-malarial chemotherapy is thought to depend is the patient’s immune status[8]. This is a subject of some importance because evidence of interactions may influence our use of
chemotherapy in areas with drug resistance, as well as an assessment of the value of suboptimal vaccines. The aim of this study was to investigate whether antibodies can play any direct contributory role in complementing anti-malarial drug therapeutic response, and, if so, whether this was associated with \textit{P. falciparum} malaria treatment outcomes.

**Methods**

**Study area and population**

Children in this study were aged between 0.5 and 15 years with uncomplicated malaria and were recruited in the village of Balonghin, in the Saponé health district, situated 50 km south of Ouagadougou. The population of Balonghin (approximately 1,600) belongs almost exclusively to the Mossi ethnic group and lives by subsistence farming. The climate is characteristic of the Sudanese savannah, with a dry season from November to May (low transmission season) and a rainy season from June to October (high transmission season). Malaria transmission is markedly seasonal, and most transmission occurs during the rainy season. The main vectors are Anopheles gambiae and Anopheles funestus. \textit{Plasmodium falciparum} is the predominant malaria parasite, accounting for more than 95\% of infections in children under five years of age [8]. From February to May, the number of bites per person per night (Entomological Inoculation Rate, EIR) due to \textit{An. gambiae} s.l. is negligible. However, the EIR increases from June to September, then decreases again from September to November and remains low until the next rainy season. The use of insecticide-treated nets in this area is very low, estimated at 1.3\%. In addition, the use of indoor residual spraying is non-existent and relies on subsistence farming.

The aim of this study was to investigate whether antibodies can play any direct contributory role in complementing anti-malarial drug therapeutic response, and, if so, whether this was associated with \textit{P. falciparum} malaria treatment outcomes.

Follow-up study through biweekly home visits to assess the efficacy of the two drugs, chloroquine and sulphadoxine/pyrimethamine, from early July to October. This study is a sub-cohort of a study which study flow is described elsewhere [8]. Drug allocation was performed randomly using epi-info software. Malaria episode was defined as fever (axillary temperature more or equal to 37.5°C) plus 5,000 \textit{P. falciparum} asexual parasites/\mu l. The WHO 2003 guidelines were used for assessment of drug efficacy[10].

**Malaria diagnosis**

Thick and thin blood films were air-dried, thin blood films were fixed with methanol, and both were stained with 3\% Giemsa. Parasite count was performed using microscopy, by experienced technicians. One hundred high power fields were examined and the number of malaria parasites of each species and stage were recorded. The parasite count was expressed as number of asexual parasites per microliter of blood and was calculated assuming a fixed white cell count of 8,000/\mu l. A slide was declared negative if no parasites were found after 100 high-power field examinations.

**Immunological assessment by ELISA**

Antibody assays were performed in a blinded fashion by personnel without knowledge of the microscopic and clinical results of the patients. Levels of specific antibodies (IgG, IgM, and IgG subclasses) were measured by ELISA, using the MSP3 long synthetic peptide (MSP3), recombinant GLURP from \textit{Escherichia coli}, and recombinant MSP1-19 from Baculovirus. The ELISA was done according to the Afro Immuno Assay standard operating procedures (SOP number AIA-007-03; AIA-001-03; AIA-013-03), which have been described elsewhere[11]. In brief, microtiter plates (NUNC - Maxisorp F 96 439454) were coated with long synthetic peptides LR55 MSP3 (1 \mu g/ml), recombinant GLURP27-500 (0.5 \mu g/ml) and recombinant MSP1-19 (1 \mu g/ml), incubated overnight at 4°C, and blocked with 3\% dry non-fat milk powder in PBS-Tween 20 for one hour. Plasma samples, diluted 1: 200 (IgG and IgM) or 1: 25 (IgG subclasses), were added in duplicate and incubated at room temperature for two hours. Plates were washed four times between steps. Plates were developed with either peroxidase-conjugated goat anti-human IgG or peroxidase-conjugated goat anti-human IgM (secondary antibody) (Caltag - H10007, H 15007). For IgG subclasses, the secondary antibody was a mouse anti-human monoclonal IgG subclass (Sigma I-9513, clone HP-6002 for IgG1 and IgG2; Sky Bio, M08011, clone ZG4 for IgG3 and Sky Bio, M11014, clone RJ4 for IgG4), and results were visualized using peroxidase-conjugated goat anti-mouse IgG (Caltag M3007). Bound secondary antibody for IgG and IgM and
tertiary antibody for IgG subclasses were quantified by colour, using ready-to-use TMB (3, 3’-5, 5’-Tetramethyl-benzidine) substrate. Optical density (OD) was read at 450 nm with a reference at 620 nm in a plate reader (Multiskan Ascent, Finland), and the OD values of the test sample were converted into arbitrary units (AU) by means of a standard curve on each plate. The positive controls were from malaria-positive Liberian plasma samples and the negative controls were from Danish plasma samples from Statens Serum Institute (Copenhagen, Denmark).

Data analysis
Data entry of case report forms for surveillance of malaria episodes was performed using EPI info version 6.0. Data generated from assays in the form of ELISA OD values were converted into Microsoft Excel worksheets using the Auditable Data Analysis and Management System for ELISA (ADAMSEL). Datasets were then transferred to Stata version 8.0 for analysis [12]. Continuous variables were log transformed. Age was coded into categories: 0.5-3, 4-5, 6-10, and > 10 years. Levels of antibodies were compared between age and drug efficacy groups using a Student’s t-test. Linear regression was fitted to account for the effect of age and sex on the efficacy of the drugs used. Arbitrary units for total IgG and IgG subclasses were compared between age categories using ANOVA.

Results
Characteristics of the study cohort
The study population consisted of 248 children, aged 0.5 to 15 years, living in the village of Balonghin. The children were selected on the basis of a general census of the village population. They all had AA genotypes for haemoglobin. Regarding gender, 55.2% were male and 44.8% were female. The mean age was 4.07 years. The main malaria species was \textit{P. falciparum}, with a geometric mean of 11,777 (9,182.954-15,104.28) parasites/μL.

Drug efficacy in the treatment of uncomplicated \textit{Plasmodium falciparum} malaria in the different age groups
The rate of drug failure (corrected with PCR) in the village of Balonghin (a rural area) was very high for both drugs used during the follow-up period (Figure 1). The rate of early treatment failure (ETF) was 14% for CQ and 11% for SP. The rate of late treatment failure (LTF) was 78% for CQ and 51% for SP. The overall failure rate for both drugs was 92% and 62% for CQ and SP with an Adequate Clinical and Parasitological Response (ACPR) of 8% and 38%, respectively (Figure 1). The failure of both drugs was more pronounced in younger children compared with older ones: 98.3% vs 47.3% for CQ and 69.2% vs 0% for SP for younger vs older children, respectively.

Association of antibody levels and efficacy of each drug in the treatment of uncomplicated \textit{Plasmodium falciparum} malaria
To investigate whether the treatment efficacy for each of the drugs assessed was associated with a background of immunity, antibody responses to the investigated antigens (MSP3, MSP1-19, and GLURP) were compared according to each drug’s efficacy. Children were assumed to be “protected” if they were able to clear the parasites during the follow-up period, and “unprotected” if they failed to clear the parasites during this period. It appears that in the CQ group, total IgG (3.55 [3.31-3.78] vs 3.18 [3.12-3.25]; P = 0.01), IgG1 (0.98 [0.53-1.44] vs 0.44 [0.37-0.52]; P = 0.01), and IgG2 (0.42 [0.23-0.61] vs 0.21 [0.18-0.25]; P = 0.001) against MSP3 were all strongly associated with drug efficacy. The same trend was observed for IgG (3.91 [3.43-4.39] vs 0.44 [0.37-0.52]; P = 0.01) and IgM (2.20 [1.41-2.99] vs 0.97 [0.86-1.08]; P = 0.01) against GLURP. For the SP group, with the exception of IgG3 (1.35 [0.67-2.04] vs. 0.67 [0.37-0.97]; P = 0.03) against MSP3, none of the other antigens showed any relationship between efficacy and antibody levels (Table 1). When adjusted for age only IgM to MSP1-19 and GLURP and IgG2 to MSP1-19 in the chloroquine group have shown significant relationship between drug efficacy and antibodies levels.

Relationship between age and level of total IgG, IgG subclasses, and IgM responses to MSP3, MSP1-19, and GLURP
The study population was categorized by age group to see whether there was a correlation between antibody levels and age. The antibody levels were compared between age groups using a Student’s t-test. The general profile of the geometric mean (95% confidence interval) of the antibody levels was found to increase rapidly with age (Table 2), with the following exceptions: IgM to MSP3; IgG1, IgG4, and IgG to MSP1-19; and IgG4 to GLURP. The antigens GLURP and MSP3 responded well, with more than two-fold and three-fold higher antibody levels in older children (> 10 years) than in younger (0.5-3 years) ones, respectively. Cytophilic IgG antibodies (IgG1 & IgG3) were by far more highly expressed than non-cytophilic IgG antibodies (IgG2 & IgG4) (Table 2).

Discussion
The data show high rates of failure for both drugs. The same trend was observed during a follow-up study of the two mentioned drugs in 2003, in Pissy, a neighbourhood in the capital city Ouagadougou (urban area) with
LTF levels of 69.5% for CQ and 14.6% for SP[13]. These data, combined with others from several malaria endemic countries, show the real state of resistance to these drugs, which have been used for a long time as first and second line drug treatments for uncomplicated malaria in many malaria endemic countries throughout the world[14,15]. This raises a major point about the emergence of the need for a change in drug policy to a more effective one, such as combination therapy, which is recommended by the WHO guidelines in many malaria-endemic areas[16]. Resistance to anti-malarial drugs is proving to be a challenging problem for malaria control in most parts of the world. Since the early 1960s, the sensitivity of the parasites to chloroquine, the best and most widely used drug for treating malaria, has been on the decline[17]. In the present study, the higher rates of drug failure for both CQ and SP are far above the levels at which the WHO recommends a change in drug policy. In Burkina Faso in 2005, because of the high rates of resistance to CQ and SP, used as first and second

![Figure 1: Chloroquine (CQ) and sulphadoxine/pyrimethamine (SP) efficacy (%).](image)

**Table 1 Relationship between antibodies levels and drug efficacy in treatment of uncomplicated *P. falciparum* malaria**

| Antigens | IgG Type | Protected GM*(95%CI) | N | Unprotected GM*(95%CI) | N | P | P* | Protected GM*(95%CI) | N | P | P* |
|----------|----------|----------------------|---|-----------------------|---|----|----|-----------------------|---|----|----|
| MSP3     | IgG      | 3.55(3.31-3.78)      | 16 | 3.18(3.12-3.25)       | 179 | 0.001 | 0.78 | 3.42(3.17-3.66)       | 20 | 3.26(3.09-3.43) | 33 | 0.27 | 0.79 |
|          | IgM      | 1.34(1.16-1.53)      | 16 | 1.32(1.19-1.45)       | 179 | 0.91 | 0.53 | 1.48(1.06-1.90)       | 20 | 1.40(1.06-1.73) | 33 | 0.75 | 0.73 |
|          | IgG1     | 0.98(0.53-1.44)      | 16 | 0.44(0.37-0.52)       | 179 | 0.001 | 0.22 | 0.38(0.23-0.54)       | 20 | 0.56(0.27-0.64) | 33 | 0.89 | 0.25 |
|          | IgG2     | 0.42(0.23-0.61)      | 16 | 0.21(0.18-0.25)       | 179 | 0.001 | 0.19 | 0.29(0.13-0.44)       | 20 | 0.18(0.13-0.23) | 33 | 0.09 | 0.69 |
|          | IgG3     | 1.10(0.64-1.69)      | 16 | 0.84(0.67-1.01)       | 179 | 0.12 | 0.48 | 1.35(0.67-2.04)       | 20 | 0.67(0.37-0.97) | 33 | 0.03 | 0.35 |
|          | IgG4     | 0.04(0.01-0.09)      | 16 | 0.01(0.008-0.01)      | 179 | 0.01 | 0.29 | 0.03(0.001-0.08)      | 20 | 0.01(0.006-0.02) | 33 | 0.32 | 0.91 |
| MSP1-19  | IgG      | 3.25(2.85-3.65)      | 16 | 3.19(3.10-3.28)       | 179 | 0.69 | 0.72 | 3.11(2.92-3.31)       | 20 | 3.22(3.01-3.44) | 33 | 0.47 | 0.46 |
|          | IgM      | 1.12(0.85-1.39)      | 16 | 1.25(1.16-1.34)       | 179 | 0.41 | 0.01 | 1.53(1.20-1.85)       | 20 | 1.30(1.09-1.50) | 33 | 0.19 | 0.77 |
|          | IgG1     | 1.67(0.95-2.38)      | 16 | 1.38(1.23-1.53)       | 179 | 0.27 | 0.50 | 1.38(0.98-1.78)       | 20 | 1.20(0.87-1.52) | 33 | 0.47 | 0.29 |
|          | IgG2     | 0.28(0.16-0.40)      | 16 | 0.23(0.19-0.27)       | 179 | 0.43 | 0.02 | 0.22(0.14-0.31)       | 20 | 0.19(0.14-0.24) | 33 | 0.48 | 0.73 |
|          | IgG3     | 0.85(0.54-1.16)      | 16 | 0.62(0.54-0.70)       | 179 | 0.12 | 0.85 | 0.63(0.45-0.81)       | 20 | 0.47(0.34-0.60) | 33 | 0.14 | 0.18 |
|          | IgG4     | 0.03(0.002-0.07)     | 16 | 0.03(0.009-0.08)      | 179 | 0.95 | 0.61 | 0.005(0.001-0.01)     | 20 | 0.04(0.003-0.07) | 33 | 0.14 | 0.13 |
| GLURP    | IgG      | 3.91(3.43-4.39)      | 16 | 3.48(3.38-3.58)       | 179 | 0.01 | 0.68 | 3.58(3.33-3.82)       | 20 | 3.47(3.24-3.70) | 33 | 0.54 | 0.68 |
|          | IgM      | 2.20(1.43-2.99)      | 16 | 0.97(0.86-1.08)       | 179 | 0.001 | 0.02 | 1.08(0.82-1.33)       | 20 | 0.87(0.68-1.05) | 33 | 0.17 | 0.89 |
|          | IgG1     | 1.39(0.96-1.81)      | 16 | 1.05(0.92-1.17)       | 179 | 0.13 | 0.77 | 1.10(0.77-1.43)       | 20 | 1.20(0.84-1.56) | 33 | 0.69 | 0.36 |
|          | IgG2     | 0.68(0.48-0.88)      | 16 | 0.46(0.38-0.54)       | 179 | 0.11 | 0.76 | 0.54(0.29-0.79)       | 20 | 0.50(0.29-0.72) | 33 | 0.82 | 0.65 |
|          | IgG3     | 0.77(0.59-0.94)      | 16 | 0.64(0.57-0.71)       | 179 | 0.32 | 0.34 | 0.72(0.55-0.94)       | 20 | 0.59(0.48-0.71) | 33 | 0.24 | 0.63 |
|          | IgG4     | 0.006(0.003-0.016)   | 16 | 0.02(0.002-0.05)      | 179 | 0.57 | 0.30 | 0.04(0.003-0.12)      | 20 | 0.02(0.002-0.05) | 33 | 0.63 | 0.83 |

N: number of children, GM*: geometric mean of Ig; P value not adjusted for age and sex, P*: P value adjusted for age and sex.
line treatments, respectively, the anti-malarial drug policy was changed to combination therapy, as recommended [13]. These results showed that the level of total IgG and IgM against the three antigens, with the exceptions of IgM to MSP3 and IgG and IgM to MSP1-19, was higher in the group of children whose malaria was cured compared with those whose treatment failed, despite similar anti-malarial treatment regimens. A similar finding had already been observed in other malaria endemic areas, in case-control studies [8,18,19], suggesting a supportive role for humoral antibodies in the therapeutic response to anti-malarial drugs. As previously reported [8,18,19], in most cases antibody responses (IgG, IgM and IgG subclasses) to the tested antigens increased with increasing age, in the current paper when adjusted with age as confounding factor, no significant relationship was found between antibodies levels and drug’s efficacy except for IgM to MSP1-19 and GLURP and IgG2 to MSP1-19 in the chloroquine group. These results are consistent with previous studies that have suggested a protective role for IgM antibodies against malaria infection [20,21] and for IgG2 associated with lower risk of infection. Nevertheless, evidence that anti-malarial treatment responses in immune patients were always better than those in non-immune patients was first observed by Yorke and collaborators while investigating malaria therapy for general paralysis in early 1942 [18]. The fact that antibodies play an important role in the development of premunition has been well demonstrated [22-24]. Data obtained in the current study have shown that antibody responses, mainly to MSP3 and GLURP antigens, which are predominantly cytophilic isotypes, are associated with protection. Several immuno-epidemiological studies performed in geographically separated areas of Africa have reached the same conclusion; that high levels of two major malaria vaccine candidate antigens (GLURP and MSP3) stimulate production of specific cytophilic antibodies that are significant predictors of protection against clinical malaria [1,11,25]. This provides epidemiological support for the concept that antibodies against GLURP and MSP3 can actively control parasite multiplication in vivo through cooperation with cells bearing Fc II receptors [26]. The proof of a protective effect by these two antigens has lead today to a large-scale implementation of a candidate vaccine (GMZ2), which is comprised of a combination of the two molecules (GLURP and MSP3), in children under five years old in several malaria epidemiological settings in Africa. These two distinct mechanisms of parasite clearance (host immunity and drug pressure) may play complementary roles, and may thereby achieve efficacy when one mechanism alone may have been insufficient. This observation has been confirmed in a case-control study in which partial immunity of the patient was shown to play an important role even in the sensitivity of resistant parasites [24].

**Conclusion**

In malaria endemic zones, it is of paramount importance to give treatment as soon as the diagnosis is made. But it is not yet clear, however, how early treatment could modify the development of protection to further infections, and knowledge of how a primary infection with the malaria parasite may influence the immune response to...
later infections is scarce. Nevertheless, these results suggest that a background humoral immune response could be beneficial to children during anti-malarial chemotherapy. This information needs to be taken into account not only for drug treatment policy, but also for malaria vaccine development.

Acknowledgements
We wish to thank the populations of the study villages for their kind participation in this study. We thank the Ministry of Health of Burkina Faso for their cooperative support. We are grateful to the staff of Centre National de Recherche et de Formation sur le Paludisme (CNRFP), whose participation has made this study possible. This investigation received support of the African Malaria Network Trust (AMANET) and the Netherlands Ministry of Foreign Affairs (DGIS).

Author details
1Centre National de Recherche et de Formation sur le paludisme, o1 BP 2208 Ouagadougou 01, Burkina Faso. 2Department of Clinical Biochemistry, Statens Serum, 5, Orestads Boulevard, DK-2300 Copenhagen, Denmark. 3Noguchi Memorial Institute for Medical Research, Legon, P.O. Box MAA, Accra, Ghana. 4iUNRF Sciences de la Vie et de la Terre (SVT), Université de Ouagadougou, Ouagadougou, Burkina Faso. 5Group of Recherche Action en Santé, 06 BP 10248 Ouagadougou 06, Burkina Faso.

Authors contributions
AD participated in the design of the study, collected data, coordinated the study, performed statistical analysis and wrote the first draft of the manuscript. ABT, AO, ATK, MT, DD, AST and BSS participated in the design of the study, coordinated and participated in the drafting of the manuscript. IN and IS participated in the lab work and data interpretation. All the authors read and approved the final version.

Competing interests
The authors declare that they have no competing interests.

Received: 23 November 2011 Accepted: 22 March 2012 Published: 22 March 2012

References
1. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Sprent J. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005, 73:8017-8026.
2. Garraud O, Drouet A, Holm I, Perren R, Longacre S. Immune responses to Plasmodium falciparum-merozoite surface protein 1 (MSP1) antigen. II. Induction of parasite-specific immunoglobulin G in unsensitized human B cells after in vitro T-cell priming with MSP119. Immunology 1999, 97:497-505.
3. Brown GV. Progress in the development of malaria vaccines: context and constraints. Parasitology 1999, 41:429-432.
4. Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002, 415:686-693.
5. Ballyou WR, Kester KE, Stoute JA, Heppner DG. Malaria vaccines: triumphs or tribulations? Parasitology 1999, 41:403-408.
6. White NJ. Why is it that antimalarial drug treatments do not always work? Ann Trop Med Parasitol 1998, 92:449-458.
7. Richie TL, Saul A. Progress and challenges for malaria vaccines. Nature 2002, 415:694-707.
8. Nebie I, Diarra A, Ouedraogo A, Souilma I, Bougouma EC, Tiono AB, Konate AT, Chatte TH, Theisen M, Durodola D, Remarque E, Bosomprah S, Milligan P, Sirima BS. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal transmission in Burkina Faso, West Africa. Infect Immun 2008, 76:759-766.
9. Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konate AT, Cuzin-Ouatara N, Theisen M, Corradin G, Coursens S, Ouattara AS, Ibbou-Sanogo E, Sirima BS. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria? Trop Med Int Health 2008, 13:229-237.
10. OMS: Evaluation et surveillance de l’efficacité des antipaludiques pour le traitement à P. falciparum non compliqué Genève: OMS/RBM/H10/200350; 2003.
11. Lusingu JP, Vestergaard LS, Alfirevic M, Mmbando BP, Theisen M, Kitya AJ, Lennge MM, Theander TG: Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. Malar J 2005, 4:48.
12. [http://www.stata.com].
13. Gansané ANI, Soulama I, Tiono A, Diarra A, Konaté AT, Ouedraogo A, Sirima BS. Change of antimalarial first line treatment in Burkina Faso in 2005. Bull Soc Path Exot 2005, 102:31-35.
14. Bhatti PK, Alam MT, Boxer R, Shukla MM, Gautam SP, Sharma YD, Singh N: Therapeutic efficacy of chloroquine and sequence variation in pfcr gene among patients with falciparum malaria in central India. Trop Med Int Health 2010, 15:33-40.
15. Kawai A, Arita N, Matsumoto Y, Kawaiwata M, Chowdhury MS, Saito-To A: Efficacy of chloroquine plus primaquine treatment and pfcr mutation in uncomplicated falciparum malaria patients in Rangamati, Bangladesh. Parasitol Int 2011, 60:341-346.
16. WHO: Guideline for treatment of malaria Geneva: World Health Organization, 2006.
17. WHO: Malaria site: drug resistance Geneva: World Health Organization, 2006.
18. Yorke W, Macie JWS: Observations on malaria made during treatment of general paralysis. Trans R Soc Trop Med Hyg 1924, 18:13-34.
19. Mayxay M, Chotivanich P, Prukruthiyakamsee S, Newton P, Looareesuwan S, White NJ. Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am J Trop Med Hyg 2001, 65:918-923.
20. Bonnet S, Petrait S, Holm I, Fontaine T, Rosario S, Roth C, Longacre S. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. Vaccine 2006, 24:5997-6008.
21. Wahlgren M, Perlmith H, Benzer R, Björkman A, Larsson P, Lungstrom I, Patarroy MO, Perlmith P. Characterization of the humoral immune response in Plasmodium falciparum malaria. III. Factors influencing the coexpression of antibody isotypes (IgM and IgG1 to 4). Clin Exp Immunol 1986, 63:343-353.
22. McGregor IA, Carrington SP, Cohen S: Treatment of East African Plasmodium falciparum with West African human gammaglobulin. Trans R Soc Trop Med Hyg 1963, 57:170-175.
23. Mohan K, Sam H, Stevenson MM. Therapy with a combination of low doses of interleukin 12 and chloroquine completely cures blood-stage malaria, prevents severe anemia, and induces immunity to reinfection. Infect Immun 1999, 67:513-519.
24. Cravo P, Culleton R, Hunt P, Walliker D, Mackinnon MJ: Antimalarial drugs clear resistant parasites from partially immune hosts. Antimicrob Agents Chemother 2001, 45:2687-2901.
25. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000, 181:1202-1205.
26. Bouharoun-Taysou H, Ouarey C, Lune F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995, 182:409-418.